RQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedLoading investors…
Activity from announced rounds
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Advancing next-generation therapeutics for migraine and other headache disorders
Develops treatments for chronic lung diseases, focusing on viral respiratory infections
Develops preventive RNAi medicines for cardiovascular disease prediction and prevention